Rhythm Pharmaceuticals opened higher at $112.26, compared with its previous close of $112.16. In the last trading session, the stock traded between $108.88 and $112.26. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Rhythm Pharmaceuticals is now worth
$ 813.23
Giving a profit of
$ 713.23 (713.23%)
Note: Past profits do not guarantee future returns.
Rating from 15 Analysts
Today's Change
$-2.29 (-2.04%)
Day High
$112.26
Day Low
$108.88
Day Open
$112.26
Prev Close
$112.16
Volume
8,56,342
1W Return
4.47%
1M Return
22.39%
3M Return
-2.56%
6M Return
25.72%
1Y Return
10.02%
Market Cap ($ Mn)
7,617
PE Ratio
-
PB Ratio
71.59
PEG Ratio
-
ROE
-310.34%
ROCE
-60.68%
EPS (TTM)
$-0.61
1 Week
4.47%
1 Month
22.39%
3 Months
-2.56%
6 Months
25.72%
9 Months
11.58%
NICE issues positive guidance for Rhythm's IMCIVREE in BBS adults
NICE issued positive guidance for IMCIVREE for adults with BBS. Guidance expands eligibility from pediatric to adult patients. Drug is indicated for genetically confirmed Bardet-Biedl syndrome.
8 days agoRhythm Q3FY26 Results: Revenue rises 29% QoQ to $92.1 million
Global net product sales reached $92.1 million in Q3FY26, up 29% sequentially driven by the U.S. acquired HO launch. U.S. revenue contributed $67.5 million (73%) of total sales, with international revenue rising to $24.7 million. Company amended LG Chem license for bivamelagon, introducing a flat 1% royalty and $350 million in fixed payments. Secured a $750 million term loan facility at SOFR + 4.60% to fund licensing obligations and pipeline development. Launched Imcivree in Japan on October 14, expecting it to become the second-largest market after the U.S.
9 days agoWilliam Blair initiates Rhythm Pharmaceuticals with Outperform rating
William Blair initiated coverage on Rhythm Pharmaceuticals. Analyst Alethia Young assigned an Outperform rating. No specific price target or financial metrics were disclosed in the announcement.
27 days agoJP Morgan maintains Overweight on Rhythm Pharma, trims target to $145
JP Morgan maintains Overweight rating on Rhythm Pharmaceuticals. Price target lowered from $146 to $145. Analyst Priyanka Grover issued the rating and target update.
28 days agoRhythm Pharmaceuticals stock up 51.66% annually over five years
Rhythm Pharmaceuticals posted a 51.66% average annual return over five years. The stock outperformed the broader market by 40.53% annually. Current market capitalization stands at $7.26 billion. A $100 investment from five years ago is now worth $802.28.
2mo agoRhythm Pharmaceuticals secures Japan approval for IMCIVREE
Rhythm Pharmaceuticals secured marketing authorization for IMCIVREE from Japan's MHLW. The drug treats acquired hypothalamic obesity, becoming the first approved therapy in Japan. Orphan drug designation was granted by the MHLW in March 2025. Launch is expected before the end of 2026 pending final pricing.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Rhythm Pharmaceuticals is now worth
$ 813.23
Giving a profit of
$ 713.23 (713.23%)
Note: Past profits do not guarantee future returns.
